QC
AVIR icon

Quent Capital’s Atea Pharmaceuticals AVIR Stock Holding History

Quent Capital’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-35
Closed -$105 – 1336
2023
Q3 		$105 Hold
35
– – ﹤0.01% 1300
2023
Q2 		$131 Hold
35
– – ﹤0.01% 1296
2023
Q1 		$117 Hold
35
– – ﹤0.01% 1298
2022
Q4 		$168 Hold
35
– – ﹤0.01% 1282
2022
Q3 		$0 Hold
35
– – ﹤0.01% 1218
2022
Q2 		$0 Hold
35
– – ﹤0.01% 1171
2022
Q1 		$0 Buy
+35
New +$238 ﹤0.01% 1257

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Quent Capital's AVIR Position: Q4 2023 in Review

Quent Capital sold out of Atea Pharmaceuticals (AVIR) in Q4 2023, closing a stake of 35 shares — an estimated $105 sold.

Quent Capital first reported a position in AVIR in Q1 2022 and held it in 7 quarters. The position peaked at $168 in Q4 2022. 108 funds tracked by Wall St. Rank hold AVIR as of Q4 2023.

  • Quent Capital reported no remaining Atea Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Quent Capital sold 35 Atea Pharmaceuticals shares in Q4 2023, an estimated $105.
  • Quent Capital first reported a position in Atea Pharmaceuticals in Q1 2022 and held it in 7 quarters.
  • Quent Capital's Atea Pharmaceuticals position peaked at $168 in Q4 2022.
  • 108 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2023.

Based on Quent Capital's 13F filing for Q4 2023, filed 19 Jan 2024.